alendronate and methimazole

alendronate has been researched along with methimazole in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (20.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Affinito, P; Arlotta, F; Cascone, E; Di Carlo, C; Lupoli, G; Nappi, C; Nuzzo, V; Vitale, G; Vollery, M	1
Cascella, T; Ciccarelli, A; Fittipaldi, MR; Fonderico, F; Lupoli, G; Lupoli, GA; Panico, A; Vitale, G	1
Cavallo, A; Colarusso, S; Costa, L; Di Micco, L; Fittipaldi, MR; Fonderico, F; Lupoli, G; Lupoli, GA; Paglione, A; Panico, A	1

Reviews

1 review(s) available for alendronate and methimazole

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for alendronate and methimazole

Article	Year
Osteoporosis treatment in elderly hyperthyroid male patients. Journal of endocrinological investigation, 2002, Volume: 25, Issue:10 Suppl Topics: Aged; Alendronate; Antithyroid Agents; Bone Density; Drug Therapy, Combination; Femur Neck; Humans; Hyperthyroidism; Lumbar Vertebrae; Male; Methimazole; Osteoporosis	2002
[Methimazole versus methimazole and diphosphonates in hyperthyroid and osteoporotic patients]. Minerva endocrinologica, 2005, Volume: 30, Issue:2 Topics: Aged; Alendronate; Alkaline Phosphatase; Antithyroid Agents; Bone Density; Calcium; Case-Control Studies; Drug Therapy, Combination; Humans; Hyperthyroidism; Male; Methimazole; Osteoporosis; Parathyroid Hormone; Phosphorus; Treatment Outcome	2005

Other Studies

2 other study(ies) available for alendronate and methimazole

Article	Year
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 1996, Volume: 10, Issue:5 Topics: Adult; Alendronate; Bone Density; Female; Humans; Hyperthyroidism; Methimazole; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Thyrotropin; Thyroxine; Triiodothyronine	1996

Article

Year

FDA-approved drug labeling for the study of drug-induced liver injury.

Drug discovery today, 2011, Volume: 16, Issue:15-16

Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011

Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 1996, Volume: 10, Issue:5

Topics: Adult; Alendronate; Bone Density; Female; Humans; Hyperthyroidism; Methimazole; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Thyrotropin; Thyroxine; Triiodothyronine

1996